Top 5 Stocks to Buy Now
→ SpaceX will crumble without these 5 companies (From InvestPub) (Ad)tc pixel Free EFTR Stock Alerts

eFFECTOR Therapeutics (EFTR) Competitors

eFFECTOR Therapeutics logo
$0.0002 0.00 (0.00%)
As of 06/18/2026 11:06 AM Eastern
Compare

EFTR vs. CMRA, SYRS, EVLO, CALA, and STAB

Should you buy eFFECTOR Therapeutics stock or one of its competitors? MarketBeat compares eFFECTOR Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with eFFECTOR Therapeutics include Comera Life Sciences (CMRA), Syros Pharmaceuticals (SYRS), Evelo Biosciences (EVLO), Calithera Biosciences (CALA), and Statera Biopharma (STAB). These companies are all part of the "pharmaceutical products" industry.

How does eFFECTOR Therapeutics compare to Comera Life Sciences?

eFFECTOR Therapeutics (NASDAQ:EFTR) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

Comera Life Sciences has higher revenue and earnings than eFFECTOR Therapeutics. eFFECTOR Therapeutics is trading at a lower price-to-earnings ratio than Comera Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A
Comera Life Sciences$1.00M0.00-$18M-$0.31N/A

57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. 4.7% of eFFECTOR Therapeutics shares are owned by company insiders. Comparatively, 8.9% of Comera Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, eFFECTOR Therapeutics' average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company Overall Sentiment
eFFECTOR Therapeutics Neutral
Comera Life Sciences Neutral

eFFECTOR Therapeutics has a beta of 2.4, suggesting that its stock price is 140% more volatile than the broader market. Comparatively, Comera Life Sciences has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
eFFECTOR TherapeuticsN/A N/A N/A
Comera Life Sciences N/A N/A N/A

Summary

Comera Life Sciences beats eFFECTOR Therapeutics on 4 of the 7 factors compared between the two stocks.

How does eFFECTOR Therapeutics compare to Syros Pharmaceuticals?

eFFECTOR Therapeutics (NASDAQ:EFTR) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

In the previous week, eFFECTOR Therapeutics' average media sentiment score of 0.00 equaled Syros Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
eFFECTOR Therapeutics Neutral
Syros Pharmaceuticals Neutral

57.7% of eFFECTOR Therapeutics shares are held by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are held by institutional investors. 4.7% of eFFECTOR Therapeutics shares are held by company insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

eFFECTOR Therapeutics has higher earnings, but lower revenue than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than eFFECTOR Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A
Syros Pharmaceuticals$386K0.01-$164.57M-$3.03N/A

eFFECTOR Therapeutics' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
eFFECTOR TherapeuticsN/A N/A N/A
Syros Pharmaceuticals N/A -3,369.56%-97.04%

eFFECTOR Therapeutics has a beta of 2.4, meaning that its stock price is 140% more volatile than the broader market. Comparatively, Syros Pharmaceuticals has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market.

Summary

eFFECTOR Therapeutics beats Syros Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

How does eFFECTOR Therapeutics compare to Evelo Biosciences?

eFFECTOR Therapeutics (NASDAQ:EFTR) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings.

eFFECTOR Therapeutics is trading at a lower price-to-earnings ratio than Evelo Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A
Evelo BiosciencesN/AN/A-$114.53M-$8.81N/A

eFFECTOR Therapeutics has a beta of 2.4, suggesting that its share price is 140% more volatile than the broader market. Comparatively, Evelo Biosciences has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market.

In the previous week, eFFECTOR Therapeutics' average media sentiment score of 0.00 equaled Evelo Biosciences'average media sentiment score.

Company Overall Sentiment
eFFECTOR Therapeutics Neutral
Evelo Biosciences Neutral

57.7% of eFFECTOR Therapeutics shares are held by institutional investors. Comparatively, 0.3% of Evelo Biosciences shares are held by institutional investors. 4.7% of eFFECTOR Therapeutics shares are held by insiders. Comparatively, 1.0% of Evelo Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
eFFECTOR TherapeuticsN/A N/A N/A
Evelo Biosciences N/A N/A N/A

Summary

eFFECTOR Therapeutics beats Evelo Biosciences on 4 of the 6 factors compared between the two stocks.

How does eFFECTOR Therapeutics compare to Calithera Biosciences?

Calithera Biosciences (NASDAQ:CALA) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

In the previous week, Calithera Biosciences had 1 more articles in the media than eFFECTOR Therapeutics. MarketBeat recorded 1 mentions for Calithera Biosciences and 0 mentions for eFFECTOR Therapeutics. Calithera Biosciences' average media sentiment score of 0.67 beat eFFECTOR Therapeutics' score of 0.00 indicating that Calithera Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Calithera Biosciences Positive
eFFECTOR Therapeutics Neutral

57.7% of eFFECTOR Therapeutics shares are held by institutional investors. 6.6% of Calithera Biosciences shares are held by insiders. Comparatively, 4.7% of eFFECTOR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
Calithera BiosciencesN/A N/A N/A
eFFECTOR Therapeutics N/A N/A N/A

Calithera Biosciences has a beta of -1.32, meaning that its share price is 232% less volatile than the broader market. Comparatively, eFFECTOR Therapeutics has a beta of 2.4, meaning that its share price is 140% more volatile than the broader market.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calithera BiosciencesN/AN/A-$39.65MN/AN/A
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A

Summary

eFFECTOR Therapeutics beats Calithera Biosciences on 4 of the 7 factors compared between the two stocks.

How does eFFECTOR Therapeutics compare to Statera Biopharma?

Statera Biopharma (NASDAQ:STAB) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Statera BiopharmaN/AN/AN/AN/AN/A
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A

In the previous week, Statera Biopharma's average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score.

Company Overall Sentiment
Statera Biopharma Neutral
eFFECTOR Therapeutics Neutral

57.7% of eFFECTOR Therapeutics shares are held by institutional investors. 5.5% of Statera Biopharma shares are held by company insiders. Comparatively, 4.7% of eFFECTOR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
Statera BiopharmaN/A N/A N/A
eFFECTOR Therapeutics N/A N/A N/A

Statera Biopharma has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market. Comparatively, eFFECTOR Therapeutics has a beta of 2.4, indicating that its stock price is 140% more volatile than the broader market.

Summary

eFFECTOR Therapeutics beats Statera Biopharma on 3 of the 4 factors compared between the two stocks.

Get eFFECTOR Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for EFTR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EFTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EFTR vs. The Competition

Export
MetriceFFECTOR TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1K$756.26M$6.43B$12.60B
Dividend YieldN/A4.84%2.68%5.81%
P/E Ratio0.001.4124.7524.42
Price / SalesN/A120.40530.01109.07
Price / CashN/A20.0645.0755.09
Price / Book0.007.7810.806.58
Net Income-$35.81M-$5.22M$3.57B$337.17M
7 Day PerformanceN/A0.28%0.73%0.83%
1 Month PerformanceN/A2.71%1.35%3.27%
1 Year PerformanceN/A49.23%29.31%36.05%

eFFECTOR Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EFTR
eFFECTOR Therapeutics
N/A$0.00
flat		N/A-33.3%$1KN/AN/A10
CMRA
Comera Life Sciences
N/AN/AN/AN/A$3K$1.00MN/A2
SYRS
Syros Pharmaceuticals
N/A$0.00
flat		N/A-99.6%$3K$386KN/A120
EVLO
Evelo Biosciences
N/A$0.00
-66.7%		N/A-80.0%$2KN/AN/A120
CALA
Calithera Biosciences
N/A$0.00
flat		N/AN/A$1KN/AN/A60

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:EFTR) was last updated on 6/20/2026 by MarketBeat.com Staff.
From Our Partners
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely, LLC | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
How to play the Biggest IPO in stock market history!
SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...
InvestPub | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
Elon Is Quietly Doubling Down on This Bizarre Asset
Yahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon ...
Brownstone Research | Sponsoredtc pixel
An Elon Musk Fan's Warning About SPCX
Jon Najarian called Tesla in 2014 when legacy automakers dismissed it. Now he's warning investors to skip SPCX...
Banyan Hill Publishing | Sponsoredtc pixel